Dr. Jo Shen, chief executive officer of ScinoPharm Taiwan and chairman of ScinoPharm Changshu, said, “Resources from our Changshu site in Jiangsu province, China, and the Shanghai-based company Sundia will be combined to establish a robust collaboration with single-source solutions to address the increasing number of multinational companies shifting their drug development research and clinical trials in China.”
“Sundia has established long-standing and strong relationships with a number of big pharmaceuticals and small/medium-sized biotech companies from the U.S., Europe, Japan and South Korea in the fields of chemistry, biology, preclinical, formulation and API manufacture, helping our clients and partners to bring drugs to the market efficiently,” said Dr. Chen Chen, Sundia’s chief executive officer.
This alliance combines Sundia’s technical know-how and capabilities in new drug R&D with ScinoPharm’s process R&D and commercial production, especially in highly potent oncological APIs. Both companies will further support customer needs with integrated services such as drug development, research, clinical trials and commercial manufacturing.
